Mitochondrial replacement therapy: the UK and US regulatory landscapes.
作者信息
Castro Rosa J
机构信息
Department of Science and Society, Duke University, Durham, NC 27708-0187, USA.
出版信息
J Law Biosci. 2016 Nov 22;3(3):726-735. doi: 10.1093/jlb/lsw051. eCollection 2016 Dec.
Abstract
摘要
相似文献
1
Mitochondrial replacement therapy: the UK and US regulatory landscapes.线粒体替代疗法：英国和美国的监管情况
J Law Biosci. 2016 Nov 22;3(3):726-735. doi: 10.1093/jlb/lsw051. eCollection 2016 Dec.
2
Mitochondrial Replacement Techniques: Divergence in Global Policy.线粒体替代技术：全球政策的分歧。
Trends Genet. 2016 Jul;32(7):385-390. doi: 10.1016/j.tig.2016.04.006.
3
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.英国和美国药品安全撤市情况的比较分析（1971 - 1992年）：对当前监管思路和政策的启示
Soc Sci Med. 2005 Sep;61(5):881-92. doi: 10.1016/j.socscimed.2005.01.004. Epub 2005 Mar 2.
4
A systematic review and meta-analysis reveals pervasive effects of germline mitochondrial replacement on components of health.一项系统综述和荟萃分析揭示了种系线粒体替代对健康成分的普遍影响。
Hum Reprod Update. 2018 Sep 1;24(5):519-534. doi: 10.1093/humupd/dmy018.
5
Utilisation of shoulder arthroplasty in the UK.英国肩关节置换术的应用情况
Ann R Coll Surg Engl. 2004 Jan;86(1):25-8. doi: 10.1308/003588404772614641.
6
Visualizing phylogenetic tree landscapes.可视化系统发育树景观。
BMC Bioinformatics. 2017 Feb 2;18(1):85. doi: 10.1186/s12859-017-1479-1.
7
Mitochondrial Replacement Techniques: Genetic Relatedness, Gender Implications, and Justice.线粒体替代技术：遗传关联性、性别影响与公正
Gend Genome. 2017 Dec 1;1(4):129-134. doi: 10.1089/gg.2017.0016.
8
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.制药行业的药品未按批准说明书用药推广与自我监管：对英国药品使用规范管理局2003 - 2012年未按批准说明书用药推广裁决的文件分析
PLoS Med. 2016 Jan 26;13(1):e1001945. doi: 10.1371/journal.pmed.1001945. eCollection 2016 Jan.
9
Easing US restrictions on mitochondrial replacement therapy would protect research interests but grease the slippery slope.放宽美国对线粒体替代疗法的限制将保护研究利益，但也会助纣为虐。
J Assist Reprod Genet. 2019 Sep;36(9):1781-1785. doi: 10.1007/s10815-019-01529-3. Epub 2019 Aug 28.
10
Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.美卡舍明林非巴肽：胰岛素样生长因子-I/胰岛素样生长因子结合蛋白-3，美卡舍明林非巴肽，重组人胰岛素样生长因子-I/重组人胰岛素样生长因子结合蛋白-3
Drugs R D. 2005;6(2):120-7. doi: 10.2165/00126839-200506020-00008.
引用本文的文献
1
Preclinical models of mitochondrial dysfunction: mtDNA and nuclear-encoded regulators in diverse pathologies.线粒体功能障碍的临床前模型：不同病理学中的线粒体DNA和核编码调节因子
Front Aging. 2025 Jun 23;6:1585508. doi: 10.3389/fragi.2025.1585508. eCollection 2025.
2
Research Guideline Recommendations for Research on Stem Cells, Human Embryos, and Gene Editing.干细胞、人类胚胎和基因编辑研究的研究指南建议
Cell Transplant. 2025 Jan-Dec;34:9636897241312793. doi: 10.1177/09636897241312793.
3
Mitochondrial Transfer as a Novel Therapeutic Approach in Disease Diagnosis and Treatment.线粒体转移作为一种疾病诊断和治疗的新治疗方法。
Int J Mol Sci. 2023 May 16;24(10):8848. doi: 10.3390/ijms24108848.
4
Critical considerations for public engagement in stem cell-related research.公众参与干细胞相关研究的关键考量因素。
Stem Cell Reports. 2023 Feb 14;18(2):420-426. doi: 10.1016/j.stemcr.2023.01.002. Epub 2023 Feb 2.
5
Does supplementation of oocytes with additional mtDNA influence developmental outcome?向卵母细胞补充额外的线粒体DNA是否会影响发育结果？
iScience. 2023 Jan 11;26(2):105956. doi: 10.1016/j.isci.2023.105956. eCollection 2023 Feb 17.
6
Mitochondrial Replacement Therapy: In Whose Interests?线粒体替代疗法：符合谁的利益？
J Law Med Ethics. 2022;50(3):597-602. doi: 10.1017/jme.2022.98.
7
With newer tools for gene editing, is it time to revisit genetic therapy for cystic fibrosis?随着基因编辑新工具的出现，是时候重新审视囊性纤维化的基因治疗了吗？
Genes Dis. 2020 Jan 22;8(2):168-170. doi: 10.1016/j.gendis.2020.01.002. eCollection 2021 Mar.
8
Current and Emerging Clinical Treatment in Mitochondrial Disease.当前和新兴的线粒体疾病临床治疗方法。
Mol Diagn Ther. 2021 Mar;25(2):181-206. doi: 10.1007/s40291-020-00510-6. Epub 2021 Mar 1.
9
Development of mitochondrial replacement therapy: A review.线粒体替代疗法的发展：综述
Heliyon. 2020 Sep 14;6(9):e04643. doi: 10.1016/j.heliyon.2020.e04643. eCollection 2020 Sep.
10
Responsible innovation in human germline gene editing. Background document to the recommendations of ESHG and ESHRE.人类生殖系基因编辑中的负责任创新。ESHG和ESHRE建议的背景文件。
Hum Reprod Open. 2018 Jan 12;2018(1):hox024. doi: 10.1093/hropen/hox024. eCollection 2018.
Zotero 插件